Lobeline displaces [3H] dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: Comparison with d- amphetamine

Journal of Neurochemistry

Volumn 71, Issue 1, 1998, Pages 258-265

  Teng, LiHong ^a   Crooks, Peter A ^a   Dwoskin, Linda P ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

Author keywords

Dihydrotetrabenazine; Dopamine; Lobeline; Vesicular monoamine transporter

Indexed keywords

DEXAMPHETAMINE; DIHYDROTETRABENAZINE; DOPAMINE; LOBELINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CARRIER PROTEIN; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; MEMBRANE PROTEIN; NEUROPEPTIDE; NICOTINIC AGENT; SLC18A2 PROTEIN, RAT; TETRABENAZINE; TRITIUM; VESICULAR AMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINE UPTAKE; DRUG BINDING; DRUG BINDING SITE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOKING CESSATION; SYNAPSE VESICLE; ANIMAL; BINDING COMPETITION; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

LOBELLA INFLATA;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AGENTS; LOBELINE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC VESICLES; TETRABENAZINE; TRITIUM; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0031595598     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71010258.x     Document Type: Article

References (75)

1. 3H-dopamine in synaptic vesicles. Life Sci. 26, 575-578.
2. Barlow R. B. and Johnson O. (1989) Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)cytisine and (-)lobeline hydrochloride and a comparison with (-)nicotine and other nicotine-like compounds. Br. J. Pharmacol. 98, 799-808.
3. Bhat R. V., Turner S. L., Selvaag S. R., Marks M. J., and Collins A. C. (1991) Regulation of brain nicotinic receptors by chronic agonist infusion. J. Neurochem. 56, 1932-1939.
4. Brioni J. D., O'Neill A. B., Kim D. J. B., and Decker M. W. (1993) Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur. J. Pharmacol. 238, 1-8.
5. 3H-nicotine in the mouse brain. Life Sci. 44, 1123-1132.
6. Brownstein M. J. and Huffman B. J. (1994) Neurotransmitter transporters. Recent Prog. Horm. Res. 49, 27-42.
7. Clarke P. B. S. (1990) Dopaminergic mechanisms in the locomotor stimulant effects of nicotine. Biochem. Pharmacol. 40, 1427-1432.
8. Clarke P. B. S. and Kumar R. (1983) The effect of nicotine on locomotor activity in nontolerant and tolerant rats. Br. J. Pharmacol. 78, 329-337.
9. Collins A. C., Romm E., and Wehner J. M. (1990) Dissociation of the apparent relationship between nicotine tolerance and up-regulation of nicotinic receptors. Brain Res. Bull. 25, 373-379.
10. Corrigall W. A., Franklin K. B. J., Coen K. M., and Clarke P. B. S. (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107, 285-289.
11. Corrigall W. A., Coen K. M., and Adamson K. L. (1994) Self-administered nicotine activates the mesolimbic dopaminergic system through the ventral tegmental area. Brain Res. 653, 278-284.
12. Decker M. W., Majchzark M. J., and Arneric S. P. (1993) Effects of lobeline, a nicotinic receptor agonist, on learning and memory. Pharmacol. Biochem. Behav. 45, 571-576.
13. Decker M. W., Brioni J. D., Bannon A. W., and Arneric S. P. (1995) Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 56, 545-570.
14. Dorsey J. L. (1936) Control of the tobacco habit. Ann. Intern. Med. 10, 628-631.
15. Dwoskin L. P., Gerhardt G. A., Drebing C. J., Wilcox C. C., and Zahnizer N. R. (1988) Uptake and release of dopamine from rat striatal slices: comparison of PCP, amphetamine and nomifensine, in Pharmacology and Functional Regulation of Dopamine Neurons (Beart P. M., Woodruff G. N., and Jackson D. M., eds), pp. 248-250. Macmillan Press, Basingstoke.
16. El-Bizri H. and Clarke P. B. S. (1994) Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro. Br. J. Pharmacol. 111, 406-413.
17. 3H]dopamine accumulation by synaptic vesicles purified from rat striatum: inhibition by thiocyanate ion. Brain Res. 516, 155-160.
18. Erickson J. D., Schafer M. K. H., Bonner T. I., Eiden L. E., and Weihe E. (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 93, 5166-5171.
19. Fibiger H. C. and Phillips A. G. (1987) Role of catecholamine transmitters in brain reward systems: implications for the neurobiology of affect, in Brain Reward Systems and Abuse (Engle J. and Oreland L., eds), pp. 61-74. Raven Press, New York.
20. Floor E., Leventhal P. S., Wang Y., Meng L., and Chen W. Q. (1995) Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J. Neurochem. 64, 689-699.
21. Fudala P. J. and Iwamoto E. T. (1986) Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol. Biochem. Behav. 25, 1041-1049.
22. Fudala P. J., Teoh K. W., and Iwamoto E. T. (1985) Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol. Biochem. Behav. 22, 237-241.
23. Fung Y. K. and Lau Y. S. (1988) Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine treated rats. Eur. J. Pharmacol. 152, 263-271.
24. Geller I., Hartman R., and Blum K. (1971) Effects of nicotine, nicotine monomethiodide, lobeline, chlordiazepoxide, meprobamate and caffeine on a discrimination task in laboratory rats. Psychopharmacologia (Berl.) 20, 355-365.
25. Giorguieff-Chesselet M. R., Kennel M. R., Wanscheer D., and Glowinski J. (1979) Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: effect of nicotine in a low concentration. Life Sci. 25, 1257-1262.
26. Gonzalez A. M., Walther D., Pazos A., and Uhl G. R. (1994) Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Mol Brain Res. 22, 219-226.
27. 3H]-dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59, 848-856.
28. Hamann S. R. and Martin W. R. (1994) Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone, and (-)lobeline in the rat brainstem. Pharmacol. Biochem. Behav. 47, 197-201.
29. Hansch C., Leo A., and Hoekman D. (1995) Exploring QSAR, Vol. 2: Hydrophobic, Electronic and Steric Constants. American Chemical Society, Washington, D.C.
30. Harnadek G. J., Callahan R. E., Barone A. R., and Njus D. (1985) An electron transfer dependent membrane potential in chromaffin vesicle ghosts. Biochemistry 24, 384-389.
31. Harsing L. G. Jr., Sershen H., and Lajtha A. (1992) Dopamine efflux from striatum after chronic nicotine: evidence for autoreceptor desensitization. J. Neurochem. 59, 48-54.
32. Henry J. P. and Scherman D. (1989) Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem. Pharmacol. 38, 2395-2404.
33. Johnson R. G. (1988) Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68, 232-307.
34. Johnson R. G. and Scarpa A. (1976) Internal pH of isolated chromaffin vesicles. J Biol. Chem. 251, 2189-2191.
35. Johnson R. G. and Scarpa A. (1979) Protonmotive force and catecholamine transport in isolated chromaffin granules. J. Biol. Chem. 254, 3750-3760.
36. Johnson R. G., Pfister D., Carty S. E., and Scarpa A. (1979) Biological amine transport in chromaffin ghosts. J. Biol. Chem. 254, 10963-10972.
37. Kalyuzhnyy V. V. (1968) The treatment of nicotinism with the aid of lobeline and its influence on vegetative and vascular reactions. J. Neural Psychiatry 68, 1864-1870.
38. Kanner B. I., Sharon I., Maron R., and Schuldiner S. (1980) Electrogenic transport of biogenic amines in chromaffin granule membrane vesicles. FEBS Lett. 111, 83-86.
39. Kilbourn M., Lee L., Borght T. V., Jewett D., and Frey K. (1995) Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereoselective. Eur. J. Pharmacol. 278, 249-252.
40. 3H] dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem. Pharmacol. 31, 983-992.
41. 3H]-nicotine to a single class of high affinity sites in rat brain membrane. Mol. Pharmacol. 29, 448-454.
42. Liu Y., Peter D., Merickel A., Krantz D., Finn P. J., and Edwards R. H. (1996) A molecular analysis of vesicular amine transporter. Behav. Brain Res. 73, 51 -58.
43. Mantle T. J., Tipton K. F., and Garrett N. J. (1976) Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem. Pharmacol. 25, 2073-2077.
44. Martin A., Bustamante P., and Chun A. H. C. (1993) Buffer and isotonic solution, in Physical Pharmacy ( Martin A., Bustamante P., and Chun A. H. C., eds), pp. 169-189. Lea & Fibiger, Philadelphia.
45. Miller H. J., Shore P. A., and Clarke D. E. (1980) In vivo monoamine oxidase inhibition by d-amphetamine. Biochem. Pharmacol. 29, 1347-1354.
46. Nunn-Thompson C. L. and Simon P. A. (1989) Pharmacotherapy for smoking cessation. Clin. Pharmacol. 8, 710-720.
47. Olin B. R., Hebel S. K., Gremp J. L., and Hulbertt M. K. (1995) Smoking deterrents, in Drug Facts and Comparisons (Olin B. R., Hebel S. K., Gremp J. L., and Hulbertt M, K., eds), pp. 3087-3095. Lippincott, St. Louis.
48. Parker E. M. and Cubeddu L. X. (1986) Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. II. Release in the presence of vesicular transmitter stores. J. Pharmacol. Exp. Ther. 237, 193-203.
49. Peter D., Jimenez J., Liu Y., Kim J., and Edwards R. H. (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269, 7231-7237.
50. Philippu A. and Beyer J. (1973) Dopamine and noradrenaline transport into subcellular vesicles of the striatum. Naunyn Schmiedebergs Arch. Pharmacol. 278, 387-402.
51. Pletscher A., Brossi A., and Gey K. F. (1962) Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int. Rev. Neurobiol. 4, 275-306.
52. Rapier C., Lunt G. G., and Wonnacott S. (1988) Stereoselective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation. J. Neurochem. 50, 1123-1130.
53. Reavill C., Walther B., Stolerman I. P., and Testa B. (1990) Behavioral and pharmacokinetics studies on nicotine, cytisine and lobeline. Neuropharmacology 29, 619-624.
54. Risinger F. O. and Oakes R. A. (1995) Nicotine-induced conditioned place preference and conditioned place aversion in mice. Pharmacol. Biochem. Behav. 51, 457-461.
55. Romano C. and Goldstein A. (1980) Stereospecific nicotine receptors on rat brain membranes. Science 210, 647-649.
56. Rostene W., Boja J. W., Scherman D., Caroll F. I., and Kuhar M. J. (1992) Dopamine transporter: pharmacological distinction between the synaptic membrane and the vesicular transporter in rat striatum. Eur. J. Pharmacol. 218, 175-177.
57. Russell J. T., Levine M., and Njus D. (1985) Electron transfer across posterior pituitary neurosecretory vesicle membranes. J. Biol. Chem. 260, 226-231.
58. 3H]-metabolites in rat striatum by nicotine drugs. Brain Res. 242, 99-106.
59. Sanderson E. M., Drasdo A. L., McCrea K., and Wonnacott S. (1993) Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res. 617, 349-352.
60. Schechter M. D. and Rosecrans J. A. (1972) Nicotine as a discriminative cue in rats: inability of related drugs to produce nicotine-like cueing effects. Psychopharmacology 27, 379-387.
61. Scherman D. (1986) Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J. Neurochem. 47, 331-339.
62. 3H]dihydrotetrabenazine binding sites in the mouse brain and its relationship to the distribution of monoamines and their metabolites. Brain Res. 370, 176-181.
63. 3H]-Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J. Neurochem. 50, 1131-1136.
64. Sewester C. S., Threlkeld D. S., Olin B. R., Heirendt P., Simo R. A., Hinton T. L., Hebel S. K., Hagemann R. C., and Rivard R. (1997) Smoking deterrents, in Drug Facts and Comparisons (Sewester C. S., Threlkeld D. S., Olin B. R., Heirendt P., Simo R. A., Hinton T. L., Hebel S. K., Hagemann R. C., and Rivard R., eds), p. 3470. Lippincott, St. Louis.
65. Shoaib M., Stolerman I. P., and Kumar R. C. (1994) Nicotine-induced place preference following prior nicotine exposure in rats. Psychopharmacology 113, 445-452.
66. Standaert D. G. and Young A. B. (1996) Treatment of central nervous system degenerative disorders, in The Pharmacological Basis of Therapeutics, 9th edit. (Hardman J. G., Limberd L. E., Molinoff P. B., Ruddon R. W., and Gilman A. G., eds), pp. 503-519. McGraw-Hill, New York.
67. Stolerman I. P., Garcha H. S., and Mirza N. R. (1995) Dissociation between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology 117, 430-437.
68. Sulzer D. and Rayport S. (1990) Amphetamine and other psychostimulants reduce pH gradient in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5, 797-808.
69. Sulzer D., Chen T. K., Lau Y. Y., Kristensen H., Rayport S., and Ewing G. A. (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15, 4102-4108.
70. Takahashi N., Miner L. L., Sora I., Ujike H., Revay R. S., Kostic V., Jackson-Lewis V., Przedborski S., and UhI G. R. (1997) VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA 94, 9938-9943.
71. 3H] dopamine uptake. J. Pharmacol. Exp. Ther. 80, 1432-1444.
72. 3H]-dihydrotetrabenazine-binding protein from bovine adrenal medulla. J. Pharmacol. Exp. Ther. 40, 889-894.
73. Westfall T. C., Perry H., and Vickery L. (1987) Mechanisms of nicotine regulation of dopamine release in neostriatum, in Tobacco Smoking and Nicotine (Martin W. R., VanLoon G. R., Iwamoto E. T., and Davis L., eds), pp. 209-223. Plenum, New York.
74. Whiteaker P., Gracha H. S., Wonnacott S., and Stolerman I. P. (1995) Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats. Br. J. Pharmacol. 116, 2097-2105.
75. Wright I. S. and Littauer D. (1937) Lobeline sulfate: its pharmacology and use in the treatment of the tobacco habit. JAMA 109, 649-654.